Jan 04, 2001 - 4:21 pm
I'm back to pick some brains again!
I had a lumpectomy 12/14, reexcision for better margins 12/21. Tumor was 4 cm, ER/PR neg, Her2 neg, 9 on BR scale. I'm 41 and premenopausal.
I've been offered the option of having AC or CMF.
From what I've been able to find, there haven't been many studies done on the relative benefit of AC/CMF on node-negative cancer. There is a rationale that it will benefit me because it benefits node+/Her2+ cancers, and my risk factors are similar. BUT from what I've read, AC at the dosage they will be giving me also poses some risk to the heart. I need to understand what the trade-off is.
I'm trying to find out just what the stats are -- how much improvement does AC seem to have with more aggressive cancers? Anybody know?